---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-132838"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T03:10:19.551641+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "low"
source: SEC EDGAR
---

# Kymera presents Phase 1 healthy volunteer data for oral STAT6 degrader KT-621

## Summary
- Hosted conference call on June 2, 2025 to discuss Phase 1 results for KT-621, a first-in-class oral STAT6 degrader.
- Slide presentation furnished as Exhibit 99.1; specific safety, PK/PD, or efficacy data not provided in available text.
- KT-621 targets immuno-inflammatory diseases; Phase 1 study in healthy volunteers completed.

## SEC filing metadata
- accession: 0001193125-25-132838
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312525132838/0001193125-25-132838-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312525132838/d943327d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-132838
- JSON: https://secwatch.observer/filing/0001193125-25-132838.json
- Plain text: https://secwatch.observer/filing/0001193125-25-132838.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.